Dana L Casey1, Ken L Pitter1, Brian H Kushner2, Nai-Kong V Cheung2, Shakeel Modak2, Michael P LaQuaglia3, Suzanne L Wolden4. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: woldens@mskcc.org.
Abstract
PURPOSE: As part of consolidative therapy in high-risk neuroblastoma, modern protocols recommend radiation therapy (RT) both to the primary site and to sites of metastatic disease that persist after induction chemotherapy. Although there are abundant data showing excellent local control (LC) with 21 Gy directed at the primary site, there are few data describing the feasibility and efficacy of RT directed at metastatic sites of disease as part of consolidation. METHODS AND MATERIALS: All patients with neuroblastoma who received RT to metastatic sites of disease as a part of consolidative therapy at a single institution between 2000 and 2015 were reviewed. Among 159 patients, 244 metastases were irradiated. RESULTS: The median follow-up period among surviving patients was 7.4 years. Over 85% of the irradiated metastases were treated with 21 Gy (range, 10.5-36 Gy). Tumor recurrence occurred in 43 of 244 irradiated metastases (18%). The 5-year LC rate of treated metastatic sites was 81%. Metastatic sites that cleared with induction chemotherapy had improved LC compared with sites with persistent uptake on metaiodobenzylguanidine scans (LC rate, 92% vs 67%; P < .0001). LC at irradiated metastatic sites did not differ based on total number of sites irradiated or site of disease irradiated (bone vs soft tissue). Patients with bulky, resistant disease who were treated with 30 to 36 Gy had worse LC (P = .02). However, on multivariate analysis, only persistence after induction chemotherapy remained a significant prognostic factor for LC (hazard ratio, 3.7; P < .0001). Patients who had LC at irradiated metastatic sites had improved overall survival compared with those who did not (overall survival rate, 71% vs 50%; P < .0001). CONCLUSIONS: Response to chemotherapy is an important prognostic factor for LC at irradiated metastatic sites in neuroblastoma. Overall, consolidative RT appears to be an effective modality of LC. Long-term disease control can be achieved with such an approach.
PURPOSE: As part of consolidative therapy in high-risk neuroblastoma, modern protocols recommend radiation therapy (RT) both to the primary site and to sites of metastatic disease that persist after induction chemotherapy. Although there are abundant data showing excellent local control (LC) with 21 Gy directed at the primary site, there are few data describing the feasibility and efficacy of RT directed at metastatic sites of disease as part of consolidation. METHODS AND MATERIALS: All patients with neuroblastoma who received RT to metastatic sites of disease as a part of consolidative therapy at a single institution between 2000 and 2015 were reviewed. Among 159 patients, 244 metastases were irradiated. RESULTS: The median follow-up period among surviving patients was 7.4 years. Over 85% of the irradiated metastases were treated with 21 Gy (range, 10.5-36 Gy). Tumor recurrence occurred in 43 of 244 irradiated metastases (18%). The 5-year LC rate of treated metastatic sites was 81%. Metastatic sites that cleared with induction chemotherapy had improved LC compared with sites with persistent uptake on metaiodobenzylguanidine scans (LC rate, 92% vs 67%; P < .0001). LC at irradiated metastatic sites did not differ based on total number of sites irradiated or site of disease irradiated (bone vs soft tissue). Patients with bulky, resistant disease who were treated with 30 to 36 Gy had worse LC (P = .02). However, on multivariate analysis, only persistence after induction chemotherapy remained a significant prognostic factor for LC (hazard ratio, 3.7; P < .0001). Patients who had LC at irradiated metastatic sites had improved overall survival compared with those who did not (overall survival rate, 71% vs 50%; P < .0001). CONCLUSIONS: Response to chemotherapy is an important prognostic factor for LC at irradiated metastatic sites in neuroblastoma. Overall, consolidative RT appears to be an effective modality of LC. Long-term disease control can be achieved with such an approach.
Authors: Brian H Kushner; Nai-Kong V Cheung; Christopher A Barker; Kim Kramer; Shakeel Modak; Karima Yataghene; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-08 Impact factor: 7.038
Authors: Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-27 Impact factor: 7.038
Authors: Alexei L Polishchuk; Richard Li; Christine Hill-Kayser; Anthony Little; Randall A Hawkins; Jeffrey Hamilton; Michael Lau; Hung Chi Tran; Caron Strahlendorf; Richard S Lemons; Vivian Weinberg; Katherine K Matthay; Steven G DuBois; Karen J Marcus; Rochelle Bagatell; Daphne A Haas-Kogan Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-24 Impact factor: 7.038
Authors: Heather G Gatcombe; R B Marcus; Howard M Katzenstein; Mourad Tighiouart; Natia Esiashvili Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-11 Impact factor: 7.038
Authors: Michael P La Quaglia; Brian H Kushner; Wendy Su; Glenn Heller; Kim Kramer; Sara Abramson; Nancy Rosen; Suzanne Wolden; Nai-Kong V Cheung Journal: J Pediatr Surg Date: 2004-03 Impact factor: 2.545
Authors: Suzanne L Wolden; Christopher A Barker; Brian H Kushner; Haritha Bodduluri; Cesar Della-Biancia; Kim Kramer; Shakeel Modak; Nai-Kong V Cheung Journal: Pediatr Blood Cancer Date: 2008-06 Impact factor: 3.167
Authors: Wei-Ling Liang; Xiao-Fan Ye; Gong Zhong; Jian-Jun Chen; Kang-Lin Dai; Ka Leung Daniel Cheuk; Shu Mo; Bo-Shen Wang; Chun-Yu Li; Xuan-Zhu Jiang; Zhi-Yuan Xu; Li Zhou; Irene Chan; Jian-Liang Chen; Patrick Chu; Pui Wah Pamela Lee; Chi Fung Godfrey Chan Journal: Zhongguo Dang Dai Er Ke Za Zhi Date: 2022-07-15
Authors: Jaques van Heerden; Mariana Kruger; Tonya Esterhuizen; Marc Hendricks; Jennifer Geel; Ané Büchner; Gita Naidu; Jan du Plessis; Barry Vanemmenes; Ronelle Uys; G P Hadley Journal: Pediatr Surg Int Date: 2020-02-28 Impact factor: 1.827
Authors: Christine Chung; Tom Boterberg; John Lucas; Joseph Panoff; Dominique Valteau-Couanet; Barbara Hero; Rochelle Bagatell; Christine E Hill-Kayser Journal: Pediatr Blood Cancer Date: 2021-05 Impact factor: 3.167
Authors: Annu Singh; Shakeel Modak; Armand K Solano; Brian H Kushner; Suzanne Wolden; Joseph Huryn; Cherry L Estilo Journal: Pediatr Blood Cancer Date: 2021-01-28 Impact factor: 3.167
Authors: Ji Hwan Jo; Seung Do Ahn; Minji Koh; Jong Hoon Kim; Sang-Wook Lee; Si Yeol Song; Sang Min Yoon; Young Seok Kim; Su Ssan Kim; Jin-Hong Park; Jinhong Jung; Eun Kyung Choi Journal: Radiat Oncol J Date: 2019-09-30
Authors: Danny Jazmati; Sarina Butzer; Barbara Hero; Dalia Ahmad Khalil; Julien Merta; Christian Bäumer; Gina Plum; Jörg Fuchs; Friederike Koerber; Theresa Steinmeier; Sarah Peters; Jerome Doyen; Theresa Thole; Matthias Schmidt; Christoph Blase; Stephan Tippelt; Angelika Eggert; Rudolf Schwarz; Thorsten Simon; Beate Timmermann Journal: Front Oncol Date: 2021-01-20 Impact factor: 6.244
Authors: John Thomas Lucas; Daniel Victor Wakefield; Michael Doubrovin; Yimei Li; Teresa Santiago; Sara Michele Federico; Thomas E Merchant; Andrew M Davidoff; Matthew J Krasin; Barry L Shulkin; Victor M Santana; Wayne Lee Furman Journal: Clin Transl Radiat Oncol Date: 2022-03-10